Evidence
Front Pharmacol. 2024 Sep 3;15:1463187. doi: 10.3389/fphar.2024.1463187. eCollection 2024.
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, and its prevalence is rapidly increasing. Antioxidants, lipid-lowering medications, and lifestyle interventions are the most commonly used treatment options for NAFLD, but their efficacy in inhibiting steatosis progression is limited and their long-term ineffectiveness and adverse effects have been widely reported. Therefore, it is important to gain a deeper understanding of the pathogenesis of NAFLD and to identify more effective therapeutic approaches. Mitochondrial homeostasis governs cellular redox biology, lipid metabolism, and cell death, all of which are crucial to control hepatic function. Recent findings have indicated that disruption of mitochondrial homeostasis occurs in the early stage of NAFLD and mitochondrial dysfunction reinforces disease progression. In this review, we summarize the physical roles of the mitochondria and describe their response and dysfunction in the context of NAFLD. We also discuss the drug targets associated with the mitochondria that are currently in the clinical trial phase of exploration. From our findings, we hope that the mitochondria may be a promising therapeutic target for the treatment of NAFLD.
PMID:39290869 | PMC:PMC11405192 | DOI:10.3389/fphar.2024.1463187
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Targeting mitochondrial homeostasis in the treatment of non-alcoholic fatty liver disease: a review
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- Targeting cell death in NAFLD: mechanisms and targeted therapies
- Discovery of genomic loci for liver health and steatosis reveals overlap with glutathione redox genetics
- Intricate interplay between cell metabolism and necroptosis regulation in metabolic dysfunction-associated steatotic liver disease: A narrative review
- GA receptor targeted chitosan oligosaccharide polymer nanoparticles improve non-alcoholic fatty liver disease by inhibiting ferroptosis
- Chiglitazar attenuates high-fat diet-induced nonalcoholic fatty liver disease by modulating multiple pathways in mice
- Western Diet-Induced Nonalcoholic Fatty Liver Disease Mice Mimic the Key Transcriptomic Signatures Observed in Humans
- The role and mechanism of pyroptosis and potential therapeutic targets in non-alcoholic fatty liver disease (NAFLD)
- Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
- Celastrus orbiculatus Thunb. extracts and celastrol alleviate NAFLD by preserving mitochondrial function through activating the FGF21/AMPK/PGC-1α pathway
- miR-33 deletion in hepatocytes attenuates NAFLD-NASH-HCC progression
- Vaccinium spp. Berries in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Update of Preclinical and Clinical Research
- Vaccinium spp. Berries in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Update of Preclinical and Clinical Research
- Hepatic miR-363 promotes non-alcoholic fatty liver disease by suppressing INSIG1
- Effects of Mao tea from Nankun Mountain on nonalcoholic fatty liver disease in mice
- Exposure to Succinate Leads to Steatosis in Non-Obese Non-Alcoholic Fatty Liver Disease by Inhibiting AMPK/PPARalpha/FGF21-Dependent Fatty Acid Oxidation
- Prevalence of nonalcoholic fatty liver disease in Pakistan: a systematic review and meta-analysis
- Prevalence of nonalcoholic fatty liver disease in Pakistan: a systematic review and meta-analysis
- A preclinical model of severe NASH-like liver injury by chronic administration of a high-fat and high-sucrose diet in mice
- Association between nonalcoholic steatohepatitis and high serum ferritin levels in type 2 diabetes mellitus
- Sesaminol alters phospholipid metabolism and alleviates obesity-induced NAFLD
- Exerkines: Benign adaptation for exercise and benefits for non-alcoholic fatty liver disease
- Impaired SUMOylation of FoxA1 promotes nonalcoholic fatty liver disease through down-regulation of Sirt6
- Mechanism of Metabolic Dysfunction-associated Steatotic Liver Disease: Important role of lipid metabolism
- Unveiling the role of ferroptosis in the progression from NAFLD to NASH: recent advances in mechanistic understanding
- The roles and potential mechanisms of plant polysaccharides in liver diseases: a review
- Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia
- Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia
- Liquidambaric acid inhibits the proliferation of hepatocellular carcinoma cells by targeting PPARα-RXRα to down-regulate fatty acid metabolism
- Therapeutic potential of palmitoleic acid in non-alcoholic fatty liver disease: Targeting ferroptosis and lipid metabolism disorders
- From non-alcoholic fatty liver disease to metabolic-associated steatotic liver disease: Rationale and implications for the new terminology
- Ablating the glutaredoxin-2 (Glrx2) gene protects male mice against non-alcoholic fatty liver disease (NAFLD) by limiting oxidative distress
- (+)Alpha-Lipoic Acid Regulates Lipid Metabolism Gene Expression and Lipidic Profile in a Cellular Model of Fatty Acid Overload
- Trimethylamine N-oxide Induces Non-alcoholic Fatty Liver Disease by Activating the PERK Signaling Pathway
- Trimethylamine N-oxide Induces Non-alcoholic Fatty Liver Disease by Activating the PERK Signaling Pathway
- Liver Fatty Acid-binding Protein Is a More Reliable Biomarker for Liver Injury in Nonalcoholic Steatohepatitis than Other Etiologies of Hepatitis
- Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities
- A PNPLA3-Deficient iPSC-Derived Hepatocyte Screen Identifies Pathways to Potentially Reduce Steatosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Silica nanoparticles induce liver lipid metabolism disorder via ACSL4-mediated ferroptosis
- Analysis of machine learning based integration to identify the crosslink between inflammation and immune response in non-alcoholic fatty liver disease through bioinformatic analysis
- Prevalence and Association of Risk Factors According to Liver Steatosis and Fibrosis Stages among Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus in India: A Cross-sectional Study
- Haloacetamides disinfection by-products, a potential risk factor for nonalcoholic fatty liver disease
- Association between nonalcoholic fatty liver disease scores and chronic periodontitis: A retrospective cohort study
- Association between RC/HDL-C ratio and risk of non-alcoholic fatty liver disease in the United States
- Association between RC/HDL-C ratio and risk of non-alcoholic fatty liver disease in the United States
- Effect of Antidepressants on Non-Alcoholic Fatty Liver Disease and their Underlying Mechanism
- Polysaccharide of Atractylodes macrocephala Koidz alleviates NAFLD-induced hepatic inflammation in mice by modulating the TLR4/MyD88/NF-κB pathway
- Polysaccharide of Atractylodes macrocephala Koidz alleviates NAFLD-induced hepatic inflammation in mice by modulating the TLR4/MyD88/NF-κB pathway
- The burden of non-alcoholic fatty liver disease in Australia: an analysis of Global Burden of Disease study from 1990 to 2019
- Exosome prospects in the diagnosis and treatment of non-alcoholic fatty liver disease
- Exosome prospects in the diagnosis and treatment of non-alcoholic fatty liver disease
- Identification of neutrophil extracellular trap-related biomarkers in non-alcoholic fatty liver disease through machine learning and single-cell analysis
- Identification of neutrophil extracellular trap-related biomarkers in non-alcoholic fatty liver disease through machine learning and single-cell analysis
- Scale offers the possibility of identifying adherence to lifestyle interventions in patients with non-alcoholic fatty liver disease
- Adaptation of Clinical Practice Guideline for Assessment of Liver Fibrosis in Patients with Non Alcoholic Fatty Liver Disease in Isfahan Province
- Exploring Fibrosis Pathophysiology in Lean and Obese Metabolic-Associated Fatty Liver Disease: An In-Depth Comparison
- Evidence-Based Unani Pharmacotherapeutics for the Treatment of Non-Alcoholic Fatty Liver Disease: A Mechanistic Review
- Effective roles of exercise and diet adherence in non-alcoholic fatty liver disease
- The Beneficial Effect of Brazilian Propolis for Liver Damage through Endoplasmic Reticulum Stress
- Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact
- Time-restricted feeding ameliorates non-alcoholic fatty liver disease through modulating hepatic nicotinamide metabolism via gut microbiota remodeling
- Elevated ALT/AST ratio as a marker for NAFLD risk and severity: insights from a cross-sectional analysis in the United States
- Elevated ALT/AST ratio as a marker for NAFLD risk and severity: insights from a cross-sectional analysis in the United States
- Efficacy and mechanism of action of Yanxiao Di'naer formula for non-alcoholic steatohepatitis treatment based on metabolomics and RNA sequencing
- Efficacy and mechanism of action of Yanxiao Di'naer formula for non-alcoholic steatohepatitis treatment based on metabolomics and RNA sequencing
Evidence Blueprint
Targeting mitochondrial homeostasis in the treatment of non-alcoholic fatty liver disease: a review
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Targeting mitochondrial homeostasis in the treatment of non-alcoholic fatty liver disease: a review
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Targeting cell death in NAFLD: mechanisms and targeted therapies
- Understanding the role of ursodeoxycholic acid and gut microbiome in non-alcoholic fatty liver disease: current evidence and perspectives
- Akkermansia muciniphila - a Potential Next-generation Probiotic for Non-alcoholic Fatty Liver Disease
- The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease
- Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Discovery of genomic loci for liver health and steatosis reveals overlap with glutathione redox genetics
- Mitochondrial ACSS1-K635 acetylation knock-in mice exhibit altered metabolism, cell senescence, and nonalcoholic fatty liver disease
- Intricate interplay between cell metabolism and necroptosis regulation in metabolic dysfunction-associated steatotic liver disease: A narrative review
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Anthocyanin: A Potential Phytochemical Candidate for the Amelioration of Non-Alcoholic Fatty Liver Disease
- The gut-liver axis in fatty liver disease: role played by natural products
- GA receptor targeted chitosan oligosaccharide polymer nanoparticles improve non-alcoholic fatty liver disease by inhibiting ferroptosis
- Bacteroides and NAFLD: pathophysiology and therapy
- Chiglitazar attenuates high-fat diet-induced nonalcoholic fatty liver disease by modulating multiple pathways in mice
- Western Diet-Induced Nonalcoholic Fatty Liver Disease Mice Mimic the Key Transcriptomic Signatures Observed in Humans
- Chinese medicine in the treatment of non-alcoholic fatty liver disease based on network pharmacology: a review
- Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice
- Investigating the Role of Non-Coding RNA in Non-Alcoholic Fatty Liver Disease
- Novel blood and tissue-based mitochondrial D-loop mutations detected in an Iranian NAFLD patient cohort
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Silencing METTL14 alleviates liver injury in non-alcoholic fatty liver disease by regulating mitochondrial homeostasis
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- The role and mechanism of pyroptosis and potential therapeutic targets in non-alcoholic fatty liver disease (NAFLD)
- Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
- Celastrus orbiculatus Thunb. extracts and celastrol alleviate NAFLD by preserving mitochondrial function through activating the FGF21/AMPK/PGC-1α pathway
- Research progress, challenges and perspectives of phospholipids metabolism in the LXR‑LPCAT3 signaling pathway and its relation to NAFLD (Review)
- miR-33 deletion in hepatocytes attenuates NAFLD-NASH-HCC progression
- Vitamin K2 protects mice against non-alcoholic fatty liver disease induced by high-fat diet
- The therapeutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic review
- Effects of the Pituitary-targeted Gland Axes on Hepatic Lipid Homeostasis in Endocrine-associated Fatty Liver Disease-A Concept Worth Revisiting
- RNA modifications in the progression of liver diseases: from fatty liver to cancer
- RNA modifications in the progression of liver diseases: from fatty liver to cancer
- From complement to complosome in non-alcoholic fatty liver disease: When location matters
- Vaccinium spp. Berries in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Update of Preclinical and Clinical Research
- Vaccinium spp. Berries in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Update of Preclinical and Clinical Research
- Management of Cardiovascular Risk in the Non-alcoholic Fatty Liver Disease Setting
- Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
- Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
- Synthesis and biological evaluation of the novel chrysin prodrug for non-alcoholic fatty liver disease treatment
- Lipid Nanoparticle-Mediated Delivery of CRISPR-Cas9 Against Rubicon Ameliorates NAFLD by Modulating CD36 Along with Glycerophospholipid Metabolism
- The Influence of Emodin Succinyl Ethyl Ester on Non-Alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice
- PINK1/Park2-Mediated Mitophagy Relieve Non-Alcoholic Fatty Liver Disease
- Roles and Mechanisms of Choline Metabolism in Nonalcoholic Fatty Liver Disease and Cancers
- TIME-RESTRICTED FEEDING COMBINED WITH RESISTANCE EXERCISE TRAINING PREVENTS OBESITY AND IMPROVES LIPID METABOLISM IN THE LIVER OF MICE FED A HIGH-FAT DIET
- Cultivated Enterococcus faecium B6 from children with obesity promotes nonalcoholic fatty liver disease by the bioactive metabolite tyramine
- Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation
- Hepatic miR-363 promotes non-alcoholic fatty liver disease by suppressing INSIG1
- Asprosin aggravates nonalcoholic fatty liver disease via inflammation and lipid metabolic disturbance mediated by reactive oxygen species
- MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1
- Impact of lifestyle interventions on pathogenesis of nonalcoholic fatty liver disease
- Effects of Mao tea from Nankun Mountain on nonalcoholic fatty liver disease in mice
- BNIP3 in hypoxia-induced mitophagy: novel insights and promising target for non-alcoholic fatty liver disease
- Medium- and long-chain triglyceride propofol activates PI3K/AKT pathway and inhibits non-alcoholic fatty liver disease by inhibiting lipid accumulation
- Exposure to Succinate Leads to Steatosis in Non-Obese Non-Alcoholic Fatty Liver Disease by Inhibiting AMPK/PPARalpha/FGF21-Dependent Fatty Acid Oxidation
- Hypoxia-inducible factor-2alpha promotes fibrosis in non-alcoholic fatty liver disease by enhancing glutamine catabolism and inhibiting yes-associated protein phosphorylation in hepatic stellate cells
- Berberine prevents NAFLD and HCC by modulating metabolic disorders
- Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies
- Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis